Radioligand Therapy Market Size, Trend, Revenue Report 2026 to 2035
Segmentation of Radioligand Therapy Market-
Radioligand Therapy Market By Target:
- Prostate-Specific Membrane Antigen
- Cancerous bone lesions
- Somatostatin receptor type 2 (SSTR2)

Radioligand Therapy Market By Indications
- Prostate Cancer
- Neuroendocrine Tumor (NETs)
- Others Indications
Radioligand Therapy Market By Emission
- Alpha
- Beta
- Potential Pipeline
Radioligand Therapy Market By Products
- Approved Products
- Pluvicto (Pro)
- Xofigo (Pro)
- Lutathera (Pro)
- Potential Pipeline
Radioligand Therapy Market By Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Radioligand Therapy Market Snapshot
Chapter 4. Global Radioligand Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Target, Estimates & Trend Analysis
5.1. By Target, & Market Share, 2025 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following By Target:
5.2.1. Prostate-Specific Membrane Antigen
5.2.2. Cancerous bone lesions
5.2.3. Somatostatin receptor type 2 (SSTR2)
Chapter 6. Market Segmentation 2: By Indications Estimates & Trend Analysis
6.1. By Indications & Market Share, 2025 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following By Indications:
6.2.1. Prostate Cancer
6.2.2. Neuroendocrine Tumor (NETs)
6.2.3. Others Indications
Chapter 7. Market Segmentation 3: By Products Estimates & Trend Analysis
7.1. By Products & Market Share, 2025 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following By Products:
7.2.1. Approved Products
7.2.1.1. Lutathera
7.2.1.2. Zytiga
7.2.1.3. Xtandi
7.2.1.4. Xofigo
7.2.2. Potential Pipeline
Chapter 8. Market Segmentation 4: By Products Estimates & Trend Analysis
8.1. By Products & Market Share, 2025 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following By Products:
8.2.1. Alpha
8.2.2. Beta
8.2.3. Potential Pipeline
Chapter 9. Radioligand Therapy Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Radioligand Therapy Market revenue (US$ Million) estimates and forecasts By Target, 2022 - 2035
9.1.2. North America Radioligand Therapy Market revenue (US$ Million) estimates and forecasts By Indications, 2022 - 2035
9.1.3. North America Radioligand Therapy Market revenue (US$ Million) estimates and forecasts By Products, 2022 - 2035
9.1.4. North America Radioligand Therapy Market revenue (US$ Million) estimates and forecasts By Emission, 2022 - 2035
9.1.5. North America Radioligand Therapy Market revenue (US$ Million) estimates and forecasts by country, 2022 - 2035
9.2. Europe
9.2.1. Europe Radioligand Therapy Market revenue (US$ Million) By Target, 2022 - 2035
9.2.2. Europe Radioligand Therapy Market revenue (US$ Million) By Indications, 2022 - 2035
9.2.3. Europe Radioligand Therapy Market revenue (US$ Million) By Products, 2022 - 2035
9.2.4. Europe Radioligand Therapy Market revenue (US$ Million) By Emission, 2022 - 2035
9.2.5. Europe Radioligand Therapy Market revenue (US$ Million) by country, 2022 - 2035
8.3. Asia Pacific
9.3.1. Asia Pacific Radioligand Therapy Market revenue (US$ Million) By Target, 2022 - 2035
9.3.2. Asia Pacific Radioligand Therapy Market revenue (US$ Million) By Indications, 2022 - 2035
9.3.3. Asia Pacific Radioligand Therapy Market revenue (US$ Million) By Products, 2022 - 2035
9.3.4. Asia Pacific Radioligand Therapy Market revenue (US$ Million) By Emission, 2022 - 2035
9.3.5. Asia Pacific Radioligand Therapy Market revenue (US$ Million) by country, 2022 - 2035
8.4. Latin America
9.4.1. Latin America Radioligand Therapy Market revenue (US$ Million) By Target, (US$ Million) 2022 - 2035
9.4.2. Latin America Radioligand Therapy Market revenue (US$ Million) By Indications, (US$ Million) 2022 - 2035
9.4.3. Latin America Radioligand Therapy Market revenue (US$ Million) By Products, (US$ Million) 2022 - 2035
9.4.4. Latin America Radioligand Therapy Market revenue (US$ Million) By Emission, (US$ Million) 2022 - 2035
9.4.5. Latin America Radioligand Therapy Market revenue (US$ Million) by country, 2022 - 2035
8.5. Middle East & Africa
9.5.1. Middle East & Africa Radioligand Therapy Market revenue (US$ Million) By Target, (US$ Million) 2022 - 2035
9.5.2. Middle East & Africa Radioligand Therapy Market revenue (US$ Million) By Indications, (US$ Million) 2022 - 2035
9.5.3. Middle East & Africa Radioligand Therapy Market revenue (US$ Million) By Products, (US$ Million) 2021-20341
9.5.4. Middle East & Africa Radioligand Therapy Market revenue (US$ Million) By Emission, (US$ Million) 2022 - 2035
9.5.5. Middle East & Africa Radioligand Therapy Market revenue (US$ Million) by country, 2022 - 2035
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Novartis AG
10.2.2. Bayer AG
10.2.3. Telix Pharmaceuticals
10.2.4. ITM Isotope Technologies
10.2.5. Eli Lilly (via POINT Biopharma)
10.2.6. AstraZeneca (via Fusion Pharmaceuticals)
10.2.7. Radiopharm Theranostics
10.2.8. Nordic Nanovector
10.2.9. Y-mAbs Therapeutics
10.2.10. Ratio Therapeutics
10.2.11. Radionetics Oncology
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Novartis AG, Bayer AG, Telix Pharmaceuticals, ITM Isotope Technologies, Eli Lilly (via POINT Biopharma), AstraZeneca (via Fusion Pharmaceuticals), Radiopharm Theranostics,
Radioligand Therapy Market Size is valued at USD 2.65 Billion in 2025 and is predicted to reach USD 9.31 Billion by the year 2035.
The Radioligand Therapy Market Size is expected to grow at a 13.5% CAGR during the forecast period for 2026-2035.
Radioligand Therapy market is segmented on the basis of target, indications, emission and products, Prostate-Specific Membrane Antigen, Cancerous bone lesions, Somatostatin receptor type 2 (SSTR2).
North American region is the leading region of the Radioligand Therapy Market.